Find a trial

336 clinical trials grid list download

Body (indexed field)	Identifiant (ID)								Email
	22672	>=65 years old or, 18 to 64 years old and have at least 1 of the following: 1) CIRS score >6 or 2) Creatinine clearance estimated <70 mL/min - At least one lymph node >1.5 cm by CT - Absence of del 17p or TP53 mutation	Dominique Bron	LLC	Janssen	GLOW	Trial closed for recruitment	Randomized, Open-label, Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)	dominique.bron@hubruxelles.be	3	3
	22666	RECIST v1.1	Ahmad Hussein Awada	Multiple	Genoscience Pharma	GNS561-CL-I-Q-0211	Trial closed for recruitment	New Title: Phase 1/2a study to evaluate the safety, activity, and pharmacokinetics of escalating doses of GNS561 in patients with primary or secondary liver cancer. (Old Title: Phase 1/2a study to evaluate the safety, activity, and pharmacokinetics of escalating doses of GNS561 in patients with primary liver cancer)	ahmad.awada@hubruxelles.be	1	1
	22816	HER 2-/HR+	Ahmad Hussein Awada	Breast	Genentech	GO 28509	Trial closed	GO 28509 A phase II, randomized study of paclitaxel with GDC-0941 versus paclitaxel with placebo in patients with locally recurrent or metastatic breast cancer	ahmad.awada@hubruxelles.be	2	2
	22764	any line	Ahmad Hussein Awada	Multiple	Genentech-Roche	GO29674	Trial closed	A Phase Ib, Open-Label, Dose-escalation Study of the safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients with Locally Advanced or Metastatic Solid Tumors	ahmad.awada@hubruxelles.be	1	1
	28490		Thierry Berghmans	Lung	Roche	GO41892 - (CONTACT-01)	Trial closed for recruitment	A phase III, multicenter, randomized, open-label, controlled study to evaluate the efficacy, safety, and pharmacokinetics of tezolizumab given in combination with cabozantinib versus docetaxel monotherapy in patients with metastatic non-small cell lung cancer previously treated with an anti-PD-L1/PD-1 antibody and platinum-containing chemotherapy		3	3
	29413	blood and bone marrow exploration mandatory before steroids prephase /ALL B Phi negative, ALL B Phi positive, and ALL T eligible	Sebastian Wittnebel	Acute leukemia	APHP	GRAALL-2014 trial	Trial closed	Multicenter trial for the treatment of Acute Lymhoblastic Leukemia (ALL) in younger adults (18-59 years) (GRAALL-2014 trial)	Sebastian.Wittnebel@hubruxelles.be	2/3	2
	28537	Triple negative	Ahmad Hussein Awada	Breast	Erytech	GRASPA-TNBC-2018-02	Trial closed	A Randomized Phase 2/3 Study of Eryaspase in Combination with Gemcitabine and Carboplatin Chemotherapy versus Chemotherapy Alone As First-Line Treatment in Patients with Metastatic or Locally Recurrent Triple-Negative Breast Cancer	ahmad.awada@hubruxelles.be	2/3	2
	28624	1. moderate or severe cGVHD per NIH Consensus Criteria 2. KPS score > 60%. 3. Evidence of myeloid and platelet engraftment, that is, ANC > 1.0 × 10e9/L and platelet count > 50 × 10e9/L. 4. Has not received more than 3 days/72 hours of systemic corticoster	Sebastian Wittnebel	NA	Incyte Corporate	GRAVITAS-309	Trial closed	A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)	Sebastian.Wittnebel@hubruxelles.be	2/3	2
	22646	no suitable HLA-matched sibling or unrelated donor / no prior allogeneic stem cell transplantation/ AML, ALL or MDS	Philippe Lewalle	Multiple	Kiadis Pharma	HATCY study	Trial closed	A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells, versus a haploidentical HSCT with post-transplant cyclophosphamide in patients with a hematologic malignancy	philippe.lewalle@hubruxelles.be	3	3
	28578		Andrea Gombos	Breast	Seagen	HER2CLIMB-02	Trial closed for recruitment	Randomized, double-blind, Phase III Trial of tucatinib or Placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)	accueil.oncologie@hubruxelles.be	3	3
	28584	IDH1 or IDH2 +, fit for standard chemotherapy	Sebastian Wittnebel	Acute leukemia	Hovon	HOVON 150 AML/ AMLSG 29-18	Trial open for recruitment	A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy (HOVON 150 AML/ AMLSG 29-18)	Sebastian.Wittnebel@hubruxelles.be	3	3
	29135	Presence of the FLT3 mutation	Adriano Salaroli	Acute leukemia	Hovon	HOVON 156 AML / AMLSG 28-18	Trial closed for recruitment	A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy	adriano.salaroli@hubruxelles.be	3	3
	29290		Angela Loizidou		Bordet	I-SPARC	Trial closed	Immune response in patients with cancer undergoing vaccination against SARS-CoV-2 (I-SPARC; IJB-COVID-001)	angela.loizidou@hubruxelles.be	2	2
	22754	Brain metastasis	Ahmad Hussein Awada	Multiple	Lilly	I3Y-MC-JPBO	Trial closed	A phase II study of Abemaciclib in patients with brain metastases secondary to hormone receptor positive breast cancer, non-small cell lung cancer, or melanoma	ahmad.awada@hubruxelles.be	2	2